1. Home
  2. MUFG vs AZN Comparison

MUFG vs AZN Comparison

Compare MUFG & AZN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Mitsubishi UFJ Financial Group Inc.

MUFG

Mitsubishi UFJ Financial Group Inc.

HOLD

Current Price

$20.18

Market Cap

195.2B

Sector

Finance

ML Signal

HOLD

Logo AstraZeneca PLC

AZN

AstraZeneca PLC

HOLD

Current Price

$177.27

Market Cap

316.4B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
MUFG
AZN
Founded
1880
1992
Country
Japan
United Kingdom
Employees
178953
96100
Industry
Commercial Banks
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
195.2B
316.4B
IPO Year
N/A
N/A

Fundamental Metrics

Financial Performance
Metric
MUFG
AZN
Price
$20.18
$177.27
Analyst Decision
Strong Buy
Analyst Count
0
1
Target Price
N/A
N/A
AVG Volume (30 Days)
3.2M
1.9M
Earning Date
05-15-2026
04-29-2026
Dividend Yield
2.32%
1.73%
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
$4.62
$10.34
Revenue Next Year
$10.12
$6.43
P/E Ratio
$25.47
$31.91
Revenue Growth
N/A
N/A
52 Week Low
$13.20
$68.62
52 Week High
$20.23
$212.71

Technical Indicators

Market Signals
Indicator
MUFG
AZN
Relative Strength Index (RSI) 67.79 41.16
Support Level $14.80 $174.60
Resistance Level N/A $191.50
Average True Range (ATR) 0.31 3.19
MACD 0.04 -0.21
Stochastic Oscillator 89.70 18.27

Price Performance

Historical Comparison
MUFG
AZN

About MUFG Mitsubishi UFJ Financial Group Inc.

Mitsubishi UFJ Financial Group is the largest bank in Japan in terms of market capitalization and assets, with an 8.4% share of all domestic loans as of March 2025. It is the largest non-Chinese bank group globally and has a balance sheet slightly larger than those of JPMorgan Chase and HSBC Holdings. MUFG's operations in Japan account for around half of profit, banking in Thailand and Indonesia for around 15%, and equity-method earnings from Morgan Stanley most of the rest.

About AZN AstraZeneca PLC

A merger between Astra of Sweden and Zeneca of the United Kingdom formed AstraZeneca in 1999. The firm sells branded drugs across a number of major therapeutic areas, including oncology (over 40% of total revenue), cardiovascular, renal, and metabolic (over 20%), rare disease (16%), and respiratory and immunology (15%). The majority of sales comes from international markets, with the United States representing close to one-third of its sales.

Share on Social Networks: